PROKIDNEY CORP.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
PROK$1.15+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $97,805 | $99,120 |
| Marketable securities | 230,693 | 259,172 |
| Interest receivable | 1,752 | 2,447 |
| Prepaid assets | 3,014 | 4,192 |
| Prepaid clinical | 6,968 | 11,505 |
| Assets held for sale | 19,368 | 19,368 |
| Other current assets | 62 | 80 |
| Total current assets | 359,662 | 395,884 |
| Fixed assets, net | 43,326 | 42,222 |
| Right of use assets, net | 3,073 | 2,967 |
| Total assets | $406,061 | $441,073 |
| Liabilities and Shareholders' Deficit | ||
| Accounts payable | $3,122 | $3,633 |
| Lease liabilities | 857 | 765 |
| Accrued expenses and other | 27,572 | 31,137 |
| Income taxes payable | 1,257 | 682 |
| Total current liabilities | 32,808 | 36,217 |
| Income tax payable, net of current portion | 764 | 748 |
| Lease liabilities, net of current portion | 2,512 | 2,471 |
| Total liabilities | 36,084 | 39,436 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 1,368,530 | 1,396,591 |
| Shareholders’ deficit | ||
| Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 129,536,121 and 128,054,417 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 13 | 13 |
| Class B ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 163,161,681 and 163,693,707 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 16 | 16 |
| Additional paid-in capital | 218,926 | 205,736 |
| Accumulated other comprehensive gain | 75 | 130 |
| Accumulated deficit | (1,217,583) | (1,200,849) |
| Total shareholders' deficit | (998,553) | (994,954) |
| Total liabilities and shareholders' deficit | $406,061 | $441,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.